Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.

ABSTRACT: Targeted therapies against basal-like breast tumors, which are typically 'triple-negative breast cancers (TNBCs)', remain an important unmet clinical need. Somatic TP53 mutations are the most common genetic event in basal-like breast tumors and TNBC. To identify additional drivers and possible drug targets of this subtype, a comparative study between human and murine tumors was performed by utilizing a murine Trp53-null mammary transplant tumor model. We show that two subsets of murine Trp53-null mammary transplant tumors resemble aspects of the human basal-like subtype. DNA-microarray, whole-genome and exome-based sequencing approaches were used to interrogate the secondary genetic aberrations of these tumors, which were then compared to human basal-like tumors to identify conserved somat

SUBMITTER: Pfefferle AD 

PROVIDER: S-EPMC4958311 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature